ERBB3 and hepatocellular carcinoma: More importantly, it has been reported that direct activation of EGFR/HER3 by either autocrine or paracrine signaling circuit is both an adaptive process and a driving force to maintain ERK and Akt activities and subsequent HCC cell growth under sorafenib treatment[42], [43].